May 28, 2010

Slideshow: A Visual Guide to Fibromyalgia

Slideshow: A Visual Guide to Fibromyalgia

AT THE time of the polio epidemics

Government should keep watchful eye on medical aids
AT THE time of the polio epidemics, the corrective surgery that parents couldn't pay for, was sponsored by the health department, as were the aids that were required to make us mobile. There was money for surgery, crutches, boots, wheelchairs, etc. Fifteen years into our democracy and the chronically ill and disabled suffer bias from both State and the private sector.
State hospitals cannot provide many chronic medications and medical aids are refusing to cover lifesaving drugs and operations.
In 1993, I had a total shoulder replacement. I still have loose bones in my shoulder and am in need of a partial shoulder replacement. But my medical aid doesn't pay for this surgery. My arthritis and damaged shoulder cause chronic pain which makes getting through the day very difficult, but my medical aid doesn't pay for painkillers other than paracetamol.

My chronic open-angle glaucoma and Sjogren’s disease is severely affecting my eyesight but dare I hope for treatment and will my medical aid pay for it? Why does the government allow medical aids to give their members less and less for lifesaving operations and drugs every year?

Thoughts of suicide can go through one’s mind when the diseases one suffers from are so painful that one dreads waking up in the morning. Was Hitler right? Should imperfect humans like myself be gassed to make a country strong or is the government shirking its responsibilities to South Africans?
In the Eastern Cape hundreds of premature babies have died so far this year and 11 in one week in Gauteng. This government should be looking after us all but instead the gravy train is getting longer and fatter; and the designer suits and luxury cars are paid for with money that should be in government coffers feeding the poor, keeping us healthy and ensuring that our babies live. — Cilla Webster, via e-mail

Let church speak up
AS A member of the Jesus Christ Family Church, I’m concerned about the negative publicity our church is getting from the Daily Dispatch. All the bad comments about our church coming from these so-called ex- members are of great concern. In many instances ex- members are aggrieved individuals. Failure to get comment from current members of the church creates an impression that the Daily Dispatch is siding with these aggrieved individuals and therefore your stories are not balanced.
Ever since this unfortunate episode came to light there has never been a comment from the church about these allegations. If there is substance to these allegations, then let us allow the court to rule on the matter.
God willing JCF will grow bigger and better during and after this storm! — Z Ngesman, Mdantsane

• We have made, and continue to make, repeated efforts to get comment from the JCF Church. – The Editor

Clasificación Internacional de Enfermedades Codifico al Síndrome de Post Polio con el Código G14 Síndrome Postpolio   Incluye :  Síndrome postpoliomielítico  Excluyéndolo del código B91Secuelas de poliomielitis

May 26, 2010

Health Leaders Discuss Polio, Alcohol, Childhood Obesity At WHA

From the 63rd World Health Assembly (WHA) in Geneva, the Associated Press reports on what some "describe as a new strategy to get rid of" poliothat focuses on developing solutions to "problems in each country, provides more WHO monitoring, like more teleconferences, and holds governments more accountable." The plans also provide "[n]ew [polio] outbreak response plans," according to the AP.
Some "say there is little new [in this strategy] and that if this effort fails ... serious questions about whether to continue the campaign should be raised," the news service reports.

"Since WHO, the U.S. Centers for Disease Control and Prevention, UNICEF and Rotary International set out to eradicate polio in 1988, they have come tantalizingly close," the news service writes. "By 2003, cases had dropped by more than 99 percent. But progress has stalled since and several deadlines have been missed."
Despite eradication efforts, polio remains "entrenched" in Afghanistan, India, Nigeria and Pakistan. "Experts worry that as the effort enters its 22nd year, donors' patience and wallets are running thin. Sustaining the effort costs about $750 million every year," the AP reports.
According to the AP, the Bill & Melinda Gates Foundation "said the next three years are 'critically important' [to fight polio]. The foundation said their polio donations are reconsidered every year."
The piece also includes comments from current and former heads of the WHO's polio programs, who reflect on the new strategy and express concerns over what will happen if the WHO's polio program is abandoned (Cheng, 5/20).
In related news, the AP reports the WHO's 193 member states endorsed a "global strategy to reduce alcohol abuse ... Harmful drinking is the third leading risk factor for disability and premature death in the world, with 2.5 million deaths each year linked to alcohol, WHO said," the news service writes. "That figure includes 320,000 people between 15 and 29, and [WHO] said many others are sickened with heart and liver diseases, cancer and even HIV/AIDS because of alcohol abuse," according to the AP (Klapper, 5/20).
Also at the WHA, leaders "agreed on Thursday to try to reduce children's consumption of junk food and soft drinks by asking member states to restrict advertising and marketing," Reuters reports. According to the WHO, some "42 million children under the age of five are overweight, 35 million of them in developing countries," the news service writes (Nebehay, 5/20).

U.S. Surgeon-General Regina Benjamin welcomed WHO's childhood obesity plan during the WHA.
"The United States thanks the WHO for its work on the global strategy for the prevention and control of non-communicable diseases," Benjamin said, in remarksprepared for delivery during the meeting. "Because non-communicable diseases are a significant public health issue that affect both developing and developed countries, we continue to support the WHO's Action Plan for implementing the global strategy, such as the inclusion of all stakeholders in that work, as the reduction of non-communicable diseases is a shared responsibility" (5/20).

WHO Faces Questions Of Handling of H1N1
In related news, the BBC reports on how the topic of the WHO's handling of the H1N1 (swine flu) pandemic remains high on the agenda at the WHA. The piece reflects on health experts' skepticism that the virus outbreak was classified as a pandemic.

"The WHO has struggled to offer clear answers on the question of its definition of a pandemic, partly because of its policy of keeping the identity and the deliberations of its pandemic emergency advisory committee secret," the BBC writes. "The lack of transparency in its decision making process, together with the WHO's advice to countries to begin widespread vaccination against swine flu, has led some observers to suspect undue influence from the pharmaceutical industry" (Foulkes, 5/20).

Meanwhile, "[a]n expert panel investigating the World Health Organization's response to last year's swine flu outbreak said Wednesday it wants to see confidential exchanges between the U.N. body and drug companies," theAP/Washington Post reports. Committee chairman and U.S. Institute of Medicine President Harvey Fineberg said the panel plans to seek documents of correspondence between the groups before and after the WHO declared H1N1 to be a pandemic, according to the news service.

"The documents include 'contractual or letters of understanding' between the pharmaceutical industry and WHO, [Fineberg] said. 'Some of the agreements with industry that we would like to examine have been considered confidential,' but so far all of the panel's requests have been met, he said" (Jordans, 5/19).
This information was reprinted from with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery
 Henry J. Kaiser Family Foundation.

Clasificación Internacional de Enfermedades Codifico al Síndrome de Post Polio con el Código G14 Síndrome Postpolio   Incluye :  Síndrome postpoliomielítico  Excluyéndolo del código B91Secuelas de poliomielitis

May 24, 2010

Polio is a disease caused by a virus

Polio is a disease caused by a virus.

 It enters a child’s(or adult’s) body through the mouth. Sometimes it does
not cause serious illness. But sometimes it causes
paralysis (can’t move arm or leg). It can kill people who
get it, usually by paralyzing the muscles that help them

Polio used to be very common in the United States. It
paralyzed and killed thousands of people a year before we
had a vaccine for it.
IPV is a shot, given in the leg or arm, depending on age.
Polio vaccine may be given at the same time as other

Most people should get polio vaccine when they are
children. Children get 4 doses of IPV, at these ages:
􀀳 A dose at 2 months 􀀳 A dose at 6-18 months
􀀳 A dose at 4 months 􀀳 A booster dose at 4-6 years

Most adults do not need polio vaccine because they were
already vaccinated as children. But three groups of adults
are at higher risk and should consider polio vaccination:
(1) people traveling to areas of the world where polio is
(2) laboratory workers who might handle polio virus, and
(3) health care workers treating patients who could have polio.
Adults in these three groups who have never been
vaccinated against polio should get 3 doses of IPV:

􀀳 The first dose at any time,
􀀳 The second dose 1 to 2 months later,
􀀳 The third dose 6 to 12 months after the second.
Adults in these three groups who have had 1 or 2 doses
of polio vaccine in the past should get the remaining 1 or 2
doses. It doesn’t matter how long it has been since the
Earlier dose(s).

Polio - 1/1/2000
Inactivated Polio Vaccine (IPV) can prevent polio.
History: A 1916 polio epidemic in the United States killed
6,000 people and paralyzed 27,000 more. In the early
1950’s there were more than 20,000 cases of polio each
year. Polio vaccination was begun in 1955. By 1960
the number of cases had dropped to about 3,000, and by
1979 there were only about 10. The success of polio
vaccination in the U.S. and other countries sparked a
world-wide effort to eliminate polio.

Today: No wild polio has been reported in the United
States for over 20 years. But the disease is still common
in some parts of the world. It would only take one case of
polio from another country to bring the disease back if we
were not protected by vaccine. If the effort to eliminate
the disease from the world is successful, some day we
won’t need polio vaccine. Until then, we need to keep
getting our children vaccinated.

Oral Polio Vaccine: No longer recommended
There are two kinds of polio vaccine: IPV, which is the shot recommended in the United States today,
and a live, oral polio vaccine (OPV), which is drops that are swallowed.
Until recently OPV was recommended for most children in the United States. 
OPV helped us rid the country of polio, and it is still used in many parts of the world.

Both vaccines give immunity to polio, but OPV is better at keeping the disease from spreading to
other people. However, for a few people (about one in 2.4 million), OPV actually causes polio. Since
the risk of getting polio in the United States is now extremely low, experts believe that using oral
polio vaccine is no longer worth the slight risk, except in limited circumstances which your doctor
can describe. The polio shot (IPV) does not cause polio. If you or your child will be getting OPV, ask
for a copy of the OPV supplemental Vaccine Information Statement.

Adults in these three
groups who have had
3 or more doses of
polio vaccine (either
IPV or OPV) in the
past may get a booster
dose of IPV.
Ask your health care
provider for more

W H A T  Y O U  N E E D  T O  K N O W

1- What is polio?
2- Why get vaccinated?
3-Who should get polio?
4- Vaccine and when?

What should I look for?
Look for any unusual condition, such as a serious allergic
reaction, high fever, or unusual behavior.
If a serious allergic reaction occurred, it would happen
within a few minutes to a few hours after the shot. Signs
of a serious allergic reaction can include difficulty
breathing, weakness, hoarseness or wheezing, a fast heart
beat, hives, dizziness, paleness, or swelling of the throat

What should I do?
Call a doctor, or get the person to a doctor right
In the rare event that you or your child has a serious
reaction to a vaccine, there is a federal program that can
help pay for the care of those who have been harmed.
For details about the National Vaccine Injury
Compensation Program, call 1-800-338-2382 or visit the
program’s website at

• Ask your doctor or nurse. They can give you the
vaccine package insert or suggest other sources of
• Call your local or state health department’s
immunization program.
• Contact the Centers for Disease Control and Prevention
-Call 1-800-232-4636 (1-800-CDC-INFO)

-Visit the National Immunization Program’s website at
Centers for Disease Control and Prevention
National Immunization Program
Vaccine Information Statement
Polio (1/1/2000) 42 U.S.C. § 300aa-26

These people should not get IPV:
• Anyone who has ever had a life-threatening allergic
reaction to the antibiotics neomycin, streptomycin or
polymyxin B should not get the polio shot.
Anyone who has a severe allergic reaction to a polio
shot should not get another one.

These people should wait:
Anyone who is moderately or severely ill at the time the
shot is scheduled should usually wait until they recover
before getting polio vaccine. People with minor
illnesses, such as a cold, may be vaccinated.
Ask your health care provider for more information.
Some people who get IPV get a sore spot where the shot
was given. The vaccine used today has never been
known to cause any serious problems, and most people
don’t have any problems at all with it.
However, a vaccine, like any medicine, could cause
serious problems, such as a severe allergic reaction. The
risk of a polio shot causing serious harm, or death, is
extremely small.

Tell your doctor what happened, the date and time it
happened, and when the vaccination was given.

Ask your doctor, nurse, or health department to
report the reaction by filing a Vaccine Adverse
Event Reporting System (VAERS) form.

Or you can file this report through the VAERS website
at, or by calling 1-800-822-7967.
VAERS does not provide medical advice.
Reporting reactions helps experts learn about possible
problems with vaccines.

Some people should not get
4 IPV or should wait.
5 What are the risks from IPV?
6 What if there is a serious

The National Vaccine Injury
7 Compensation Program
8 How can I learn more?

May 21, 2010

Un método de tratamiento específico del SPP utilizando inmunoglobulina intravenosa (IVIG).


Grifols cierra un acuerdo con Pharmalink para la compra de los derechos de propiedad intelectual para el tratamiento del
Síndrome Post-polio (SPP) 

Incluye las patentes para Estados Unidos, Europa y Japón de un método de tratamiento específico del SPP utilizando inmunoglobulina intravenosa (IVIG).

no existe ningún medicamento aprobado para el tratamiento del SPP. 
Grifols ha suscrito un acuerdo con la compañía farmacéutica sueca Pharmalink AB para la adquisición de los derechos de propiedad intelectual para el tratamiento del síndrome post-polio (SPP). La adquisición, cuyo cierre se prevé durante las próximas semanas, incluirá las patentes para Estados Unidos, Europa y Japón de un método de tratamiento específico del SPP utilizando inmunoglobulina intravenosa (hemoderivado), además del uso sin restricciones de los datos de los ensayos clínicos realizados por PharmaLink que apoyan este método de tratamiento. Asimismo, también contempla la documentación, el know-how, las licencias en Suecia con en nombre Xepol.

Esta adquisición permitirá a Grifols abrir nuevas áreas terapéuticas en sus 
proyectos de investigación clínica. Para Ramón Riera, vicepresidente de marketing y ventas de Grifols, "explorar el tratamiento del SPP está en consonancia con nuestra misión de desarrollar terapias para grupos de pacientes con enfermedades crónicas poco frecuentes". Actualmente no existe ningún medicamento aprobado para el tratamiento del SPP. 

El síndrome postpolio (SPP) está reconocido como una enfermedad rara y l
a FDA norteamericana ha designado la inmunoglobulina intravenosa (IVIG) como medicamento huérfano para su tratamiento. Por ello, continuar con este proyecto de investigación ofrece nuevas esperanzas a los miles de personas que padecen sus síntomas debilitantes. 

Ensayos clínicos llevados a cabo por PharmaLink sobre el uso de inmunoglobulina para el tratamiento del SPP se han desarrollado utilizando la inmunoglobulina intravenosa (IVIG) de Grifols. Con esta adquisición Grifols tendrá acceso sin restricciones a los datos procedentes de estos ensayos previos y le permitirá investigar a partir de las conclusiones. La adquisición también incluye las patentes para EE.UU., Europa y Japón, que confieren a Grifols los derechos exclusivos sobre el método de tratamiento.
Sobre el Síndrome Post-polio (SPP) 

El SPP suele desarrollarse varias décadas después de superar una infección de polio aguda. El SPP se caracteriza por un incremento de la debilidad muscular, fatiga y dolor musculoesquelético. La progresiva denervación se ha señalado como la causa más importante de pérdida de fuerza muscular asociada a la infección de la polio. Los pacientes con SPP presentan un aumento de la expresión de ARNm para citocinas proinflamatorias en el líquido cefalorraquídeo, lo que sugiere un proceso inflamatorio en el sistema nervioso central. Algunos pacientes con debilidad asimétrica han aumentado el desgaste de articulaciones y músculos, incluyendo los respiratorios. Aunque rara vez es una patología mortal, los síntomas neurológicos y musculares del SPP son permanentes y debilitantes.

La epidemia de poliomielitis tuvo su punto culminante en los países occidentales en torno a 1950. Como la mayoría de las infecciones se produjeron en niños, actualmente existe un gran número de supervivientes de la polio con diferentes grados de deterioro funcional. El Instituto Nacional de Trastornos Neurológicos y Accidentes Cerebrovasculares (NINDS) de EE.UU. considera un intervalo de prevalecía del SPP del 25% al 50% (en supervivientes de infecciones de polio primarias) mientras que la OMS estima una prevalencia del 40%. Asumiendo una prevalencia del 30%, significaría que sólo en los principales países occidentales habría alrededor de 300.000 afectados con este síndrome.

Actualmente no existe un tratamiento farmacológico del SPP. Varios agentes terapéuticos han fracasado en el logro de resultados positivos. Los tratamientos se basan en fisioterapia, ejercicio ligero y el uso de dispositivos de ayuda. Los prometedores resultados del uso de inmunoglobulina pueden dar respuesta a las necesidades de algunos de los pacientes afectados con el SPP. En varios ensayos clínicos dirigidos por un equipo de científicos del Instituto Karolinska (Suecia), la inmunoglobulina ha mostrado resultados significativos en aspectos como el dolor, la capacidad de caminar y la calidad de vida (SF-36) a través de la reducción del proceso inflamatorio en el sistema nervioso de los pacientes con SPP. 

Sobre Pharmalink AB 

Pharmalink es una compañía farmacéutica sueca que desarrolla productos de alto valor añadido para enfermedades poco frecuentes. Pharmalink aprovecha su amplia experiencia en el desarrollo de productos farmacéuticos y la excelencia de la ciencia médica sueca para identificar y desarrollar productos que responden a importantes necesidades médicas no atendidas. Pharmalink ha introducido más de 15 productos farmacéuticos en el mercado.

Su estrategia está basada en la búsqueda de reformulaciones y nuevas indicaciones terapéuticas para medicamentos, lo que minimiza el riesgo en el desarrollo de fármacos. 
La estrategia de la compañía es desarrollar fármacos a través de la realización de pruebas clínicas para nuevas indicaciones terapéuticas y ofrecerlos como medicamentos huérfanos o venderlo a terceros. Pharmalink tiene actualmente dos proyectos en esta fase de desarrollo clínico, Nefecon® y BusulipoTM, y trabaja de forma activa en la concesión de nuevas y prometedores licencias para añadir a su cartera de proyectos. Para más información:
Sobre Grifols 

Grifols es un holding empresarial español especializado en el sector farmacéutico-hospitalario presente en más de 90 países.
 Desde mayo de 2006 cotiza en el Mercado Continuo Español y forma parte del Ibex-35. Actualmente es la primera empresa europea del sector de hemoderivados y el cuarto productor mundial. En los próximos años potenciará su liderazgo en la industria como compañía verticalmente integrada, gracias a las inversiones realizadas. En términos de materia prima,
 Grifols tiene asegurado el suministro de plasma con 80 centros de plasmaféresis en Estados Unidos y desde un punto de vista de capacidad de fraccionamiento, sus instalaciones productivas de Barcelona (España) y Los Ángeles (Estados Unidos) le permiten dar respuesta a la creciente demanda del mercado. No obstante, la compañía se prepara para lograr aumentos sostenidos durante los próximos 8-10 años para lo que ha puesto en marcha un ambicioso plan de inversiones. 

Grifols agrees with Pharmalink to acquire PPS drug development project

Grifols has announced that it has reached an agreement with Pharmalink to acquire intellectual property associated with the treatment of post-polio syndrome. The acquisition is expected to be finalized in the next few weeks and will include documentation, know-how, and Swedish regulatory approvals under the trade name Xepol.  Grifols will also acquire US, European and Japanese patents for a specific PPS treatment method utilizing human immunoglobulin and unrestricted use of existing Pharmalink clinical trial data supporting the treatment method.
Previous clinical trials on the use of human immunoglobulin for the treatment of PPS have been sponsored by Pharmalink using Grifols’ intravenous immunoglobulin.  Grifols’ acquisition of the Pharmalink PPS project will give Grifols unrestricted use of those data and set the stage for Grifols to investigate clinically relevant research questions growing out of prior studies.  The acquisition also includes U.S., European and Japanese patents which will effectively give Grifols exclusive rights to the treatment method.

CODIGO G "14" 
El pasado mes de febrero de 2009 y como resultado de la reunión anual del Comité de Revisión y Actualización de la Organización Mundial de la Salud, (OMS)  que tuvo lugar en Delhi, durante el mes de octubre de 2008, la Clasificación Internacional de Enfermedades, en su versión 10 (ICD-10) ha adjudicado un lugar específico al Síndrome Post-Polio (SPP) clasificándolo bajo el código "G14" y excluyéndolo del código B91  (Secuelas de poliomielitis), en el que antes ese organismo lo consideraba abarcado. Más informes

May 17, 2010

The WHO’s polio challenge

The WHO’s polio challenge: From inspiration to exhilaration

Canadian leading global battle against disease finds reasons to hope that the tipping point is near

André Picard
From Monday's Globe and Mail
Published on Sunday, May. 16, 2010 7:18PM EDT
Last updated on Monday, May. 17, 2010 3:09AM EDT
The World Health Assembly – the forum through which the World Health Organization is governed by its 193 member states – will be meeting in Geneva from Monday through May 23. Among the issues they will discuss is stepping up efforts to eradicate polio. The plan to eliminate the disease was first hatched in 1988, but has stalled in recent years. Bruce Aylward, the Canadian epidemiologist who co-ordinates the WHO global polio eradication program talks with The Globe.
In a word, how would you characterize polio eradication efforts to date – frustrating, inspiring, exhilarating?
Frustrating would not be the word. Inspiring would be closer to it. Exhilarating is what I hope to feel five years after.
But there seem to be so many obstacles.
Sure, there are challenges. Take northern Nigeria: There are real problems, but they’re not about polio eradication per se, they’re about making a quantum leap in the delivery of public services like health care. Take northern India: We’ve run into problem, problem, problem. But, again, it’s about applying modern science to breaking the back of an ancient virus. We’re either over, at or inches from the tipping point but we don’t know yet; we’ll know in six months.
If things are going well, why do we need a new plan?
The context is that, two years ago, the world assembly looked at the eradication program and said: ‘We’re deeply alarmed by the situation in Nigeria, and the fact that the last four countries [Nigeria, India, Pakistan, Afghanistan] seemed stalled in their efforts.’ So it asked for a new strategy. We suspended our five-year plan and developed a one-year plan.
So how is the new plan?
There are four elements: 1) A recognition that, in Asia and Africa, the immunity thresholds you need to stop the virus are different – they are 10-15 per cent higher in Asia, especially northern India, than in sub-Saharan Africa. 2) We learned that polio can survive in smaller populations and geographic sub-populations than scientists ever thought. 3) We have recognized that the routes of international spread of polio are largely predictable. 4) The last piece of the strategy involved the vaccine itself. Since 2005 we’ve used new vaccine – type 1 and type 3 – and they’ve worked really well. But we’ve seen a Ping-Pong effect: You get type 1 under control and type 3 pops up, and vice-versa. So now we’re going to systematically use bivalent vaccines that work well against both remaining viruses.
Are you confident this will get you over the hump?
Just five months into 2010, we’re seeing really good results. At this time last year, we had 300 cases of polio in Nigeria; this year, we have two. In northern India, in the states of Bihar and Uttar Pradesh we have not had a single case in four months.
But you have a big outbreak in Tajikistan, which has been polio-free for a long time. It’s like a hydra – cut off one head and two more appear.
It’s almost like a hydra, but it’s not: To kill a hydra you have to cut off all the heads at once. With polio, the challenge is different, it’s finding the weak point in the hydra. If you look at a map of the world, every dot you see that is a case of polio originates from eight states in northern Nigeria and two states in northern India. If you stop polio there, there will be no other outbreaks.
But the voices saying “eradication can’t work” are growing louder.
There are two groups that control whether or not eradication will get finished. First, there are the countries where infection is still endemic, in particular India and Nigeria. The other group is the G8. That’s because 50-60 per cent of the funding for the initiative comes from the G8. The day they decide ‘we’re not behind this program,’ that will be the end of eradication. The good news is that neither group is saying ‘No.’ On the contrary.
What message would you like to deliver about polio eradication to the G8 meeting in Canada?
They embraced a bold initiative on public health: to get rid of polio and to eliminate inequity in public health. After 10 years of a major investment, they are finally seeing a dramatic result in polio: months and months with very little virus in northern India and northern Nigeria. This is their chance to finish the job.

Polio Film

Entradas populares



México Post Polio Una Vida Un Camino Una Experiencia

Post Polio LITAFF A.C.
Postpoliolitaff.- Asociación Post Polio Litaff A.C Primera Organización oficial sobre Síndrome de Post Poliomielitis En México.

Polio y Efectos Secundarios SPP
- See more at:


Salk Institute

Polio Video

Polio Lungs

Polio Reinders

March Of Dimes Polio History

Erradicación de La poliomielitis

Blog Archive

Search This Blog

No more Polio

Dr. Bruno